Effects of Colchicin and Simvastatin combination therapy on the improvement of the patients with bronchectasis due to sulfur mustard gas inhalation.

Evaluation of the effects of Colchicin and Simvastatin combination therapy on the improvement of clinical and laboratory signs and symptoms of the patients with bronchectasis due to sulfur mustard gas inhalation.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015060322547N1

Enrollment

Registered

2015-10-23

Start date

2015-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other COPD due to sulfate mustard gas. Other chronic obstructive pulmonary disease

Interventions

Intervention 1: Intervention group: Simvastatin (10 mg) and Colchicine (10 mg) per day for 3 months. Intervention 2: Placebo group: two starch tablets per day for 3 months.

Treatment - Drugs

Intervention group: Simvastatin (10 mg) and Colchicine (10 mg) per day for 3 months

Placebo group: two starch tablets per day for 3 months

Eligibility

Sex/Gender

Male

Age

45 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Exposure to mustard gas during the Iran-Iraq war and have suffered from bronchiectasis (confirmed with CT scan). Exclusion criteria: Using Statins or Colchicin in the last 3 months of study starting time; Patients with bronchectasis without lung injury due to sulfur mustard gas; Exacerbation of symptoms in the past 4 weeks; Connective tissue disease; Sarcoidosis; Eosinophilic granuloma; Pneumoconiosis; Lymphoma; Carcinomatous; Smokers.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lung function. Timepoint: before intervention - 3 month after intervention. Method of measurement: spirometry.;Clinical signs and symptoms of the patients. Timepoint: before intervention - 3 month after intervention. Method of measurement: history and physical examinations.;Levels of IgE, IgM, IgA and IgG. Timepoint: before intervention - 3 month after intervention. Method of measurement: Immunoelectrophoresis.	—

Measure

Time frame

Lung function. Timepoint: before intervention - 3 month after intervention. Method of measurement: spirometry.;Clinical signs and symptoms of the patients. Timepoint: before intervention - 3 month after intervention. Method of measurement: history and physical examinations.;Levels of IgE, IgM, IgA and IgG. Timepoint: before intervention - 3 month after intervention. Method of measurement: Immunoelectrophoresis.

—

Secondary

Measure	Time frame
Health-related quality of life. Timepoint: before and 3 months after intervention. Method of measurement: the St George’s Respiratory Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProfessor Dr.Ali Emad

Shiraz University of Medical Sciences

lungdep@yahoo.com+98 917 719 0079

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026